Expectations for Gilead's Hep C pill Sovaldi and follow-on therapies remain high in 2014 and beyond.
When amateur fanboy investors interview CEOs, the questions are lobbed softballs and the responses easily deflect away from the real issues.
An FDA approval filing for Furiex's eluxadoline will be submitted in the second quarter.
Fund manager and blogger John Hempton calls out Galena Biopharma for giving away free samples of the potentially deadly fentanyl painkiller Abstral.
Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.
A quick look at the biotech sector performance in the first month of 2014.
Both Abbvie and Gilead will compete for hepatitis C patients in 2014.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Alexion is the latest drug company moving to Ireland for its low corporate tax rate.
Noted oncologist Dr. Leonard Saltz criticizes Celgene's Abraxane for costing too much and benefiting patients too little.